Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nivolumab with concurrent chemoradiotherapy in stage IIIA/B NSCLC
2014-005097-11Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoints: Grade 3 or higher pneumonitis and Progression-free survival. Started May 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005097-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005097-11.